ATYR1940 ( DrugBank: ATYR-1940, ATYR1940 )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 113 | 筋ジストロフィー | 12 |
113. 筋ジストロフィー
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02836418 (ClinicalTrials.gov) | July 12, 2016 | 30/6/2016 | Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophy | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy;Limb Girdle Muscular Dystrophy | Drug: ATYR1940 | aTyr Pharma, Inc. | NULL | Completed | 16 Years | 25 Years | All | 8 | Phase 1/Phase 2 | United States;Denmark;Italy |
| 2 | EUCTR2016-000624-25-DK (EUCTR) | 22/06/2016 | 19/04/2016 | An Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Fascioscapulohumeral Muscular Dystrophy | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Fascioscapulohumeral Muscular Dystrophy | Limb Girdle Muscular Dystrophy and Facioscapulohumeral Muscular Dystrophy MedDRA version: 19.0;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: ATYR1940 Product Code: ATYR1940 INN or Proposed INN: Not available yet Other descriptive name: ATYR1940 | aTyr Pharma, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 22 | Phase 1;Phase 2 | United States;Denmark;Italy | ||
| 3 | NCT02603562 (ClinicalTrials.gov) | March 30, 2016 | 5/11/2015 | Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy | An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy (FSHD) | Biological: ATYR1940;Biological: Placebo | aTyr Pharma, Inc. | NULL | Completed | 12 Years | 25 Years | All | 8 | Phase 1/Phase 2 | United States;France;Italy |
| 4 | EUCTR2015-001910-88-DK (EUCTR) | 17/12/2015 | 30/06/2015 | A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Facioscapulohumeral Muscular Dystrophies | An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Facioscapulohumeral Muscular Dystrophies | Limb Girdle Muscular Dystrophy and Facioscapulohumeral Muscular Dystrophy MedDRA version: 19.0;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: ATYR1940 Product Code: ATYR1940 INN or Proposed INN: Not available yet | aTyr Pharma, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 1;Phase 2 | France;United States;Denmark;Italy | ||
| 5 | NCT02579239 (ClinicalTrials.gov) | November 5, 2015 | 28/9/2015 | The Safety and Biological Activity of ATYR1940 in Patients With Limb Girdle or Facioscapulohumeral Muscular Dystrophies | An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies | Limb-Girdle Muscular Dystrophies;Facioscapulohumeral Muscular Dystrophy | Biological: ATYR1940;Biological: Placebo | aTyr Pharma, Inc. | NULL | Completed | 18 Years | 75 Years | All | 18 | Phase 1/Phase 2 | United States;Denmark;France;Italy |
| 6 | NCT02531217 (ClinicalTrials.gov) | September 2015 | 25/6/2015 | Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy - Study Extension | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients With Fascioscapulohumeral Muscular Dystrophy (FSHD) | Facioscapulohumeral Muscular Dystrophy | Biological: ATYR1940 | aTyr Pharma, Inc. | NULL | Completed | 18 Years | 65 Years | All | 9 | Phase 1/Phase 2 | United States;Italy;Netherlands |
| 7 | EUCTR2015-001912-36-NL (EUCTR) | 04/08/2015 | 22/06/2015 | A Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Exposure of ATYR1940 in Adult Patients with Genetic Myopathy | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients with Facioscapulohumeral Muscular Dystrophy (FSHD) | Facioscapulohumeral muscular dystrophy MedDRA version: 19.0;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: ATYR1940 Product Code: ATYR1940 INN or Proposed INN: Not available yet Other descriptive name: ATYR1940 | aTyr Pharma, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 32 | Phase 1;Phase 2 | United States;Netherlands;Italy | ||
| 8 | EUCTR2014-001753-17-NL (EUCTR) | 19/09/2014 | 03/06/2014 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Activity of ATYR1940 in Adults with Genetic Myopathy | A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients with Molecularly Defined Genetic Muscular Dystrophies | Facioscapulohumeral muscular dystrophy MedDRA version: 17.1;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: ATYR1940 Product Code: ATYR1940 INN or Proposed INN: N/A | aTyr Pharma, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 44 | Phase 1;Phase 2 | United States;France;Netherlands;Italy | ||
| 9 | NCT02239224 (ClinicalTrials.gov) | August 2014 | 7/9/2014 | Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients With Muscular Dystrophy | A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Biological Activity of ATYR1940 in Adult Patients With Molecularly Defined Genetic Muscular Dystrophies | Facioscapulohumeral Muscular Dystrophy (FSHD) | Biological: Placebo;Biological: ATYR1940 | aTyr Pharma, Inc. | NULL | Completed | 18 Years | 65 Years | All | 20 | Phase 1/Phase 2 | United States;France;Italy;Netherlands |
| 10 | EUCTR2014-001753-17-IT (EUCTR) | 30/07/2014 | 13/06/2014 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Activity of ATYR1940 in Adults with Genetic Myopathy | A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients with Molecularly Defined Genetic Muscular Dystrophies | Facioscapulohumeral muscular dystrophy MedDRA version: 17.0;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: ATYR1940 Product Code: ATYR1940 INN or Proposed INN: N/A | aTyr Pharma, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 44 | Phase 1;Phase 2 | United States;France;Netherlands;Italy | ||
| 11 | EUCTR2016-000624-25-IT (EUCTR) | 19/01/2021 | An Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Fascioscapulohumeral Muscular Dystrophy | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Fascioscapulohumeral Muscular Dystrophy - na | Limb Girdle Muscular Dystrophy and Facioscapulohumeral Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: ATYR1940 Product Code: ATYR1940 | ATYR PHARMA, INC. | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 1;Phase 2 | Denmark;Italy | |||
| 12 | EUCTR2014-003346-27-IT (EUCTR) | 19/01/2021 | A Study to Evaluate the Safety, Tolerability, Immunogenicity and Biological Activity of ATYR1940 in Patients With Pediatric Onset FHSD | An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy - na | Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10064087;Term: Facioscapulohumeral muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: ATYR1940 Product Code: ATYR1940 | ATYR PHARMA, INC. | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 1;Phase 2 | France;United States;Italy |